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Background: Retinal artery occlusion (RAO) is an ischemic vascular damage of the retina, 
which frequently leads to sudden, mostly irreversible loss of vision. In this study, blood throm-
bophilic factors as well as cardiovascular risk factors were investigated for their relevance to 
this pathology. Thrombophilic risk factors so far not evaluated were included in the study.
Patients and methods: 28 RAO patients and 81 matched control subjects were examined. 
From blood samples, protein C, protein S, antithrombinopathy, and factor V (Leiden) mutation 
(FV), factor II gene polymorphism, factor VIII C level, plasminogen activity, lipoprotein(a) and 
ﬁ  brinogen levels, hyperhomocysteinemia and presence of anticardiolipin – antiphospholipid 
antibodies were investigated. Possibly relevant pathologies such as diabetes mellitus, hyperten-
sion, and ischemic heart disease were also registered. Statistical analysis by logistic regression 
was performed with 95% conﬁ  dence intervals.
Results: In the group of patients with RAO only the incidence of hypertension (OR: 3.33, 
95% CI: 1.30–9.70, p = 0.014) as an average risk factor showed signiﬁ  cant difference, but 
thrombophilic factors such as hyperﬁ  brinogenemia (OR: 2.9, 95% CI: 1.29–6.57, p = 0.010) 
and the presence of FV (Leiden mutation) (OR: 3.9, 95% CI: 1.43–10.96, p = 0.008) increased 
the chances of developing this disease.
Conclusions: Our results support the assumption that thrombophilia may contribute to the 
development of RAO besides vascular damage due to the presence of cardiovascular risk fac-
tors. Further studies are needed, however, to justify the possible use of secondary prophylaxis 
in form of anticoagulant/antiplatelet therapy.
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Introduction
Von Graefe (1859) was the ﬁ  rst to describe the classic clinical picture of retinal artery 
occlusion. He observed a man who had experienced a sudden loss of vision in the 
right eye with the following fundus ﬁ  ndings: pale disk, attenuated arteries and veins, 
and cloudy retina that produced a macular cherry-red spot.
Clinicians usually differentiate acute retinal arterial occlusion (RAO), such as 
central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO). 
Fundoscopy characteristics of CRAO patients are the pale, ischemic retinal edema 
with a cherry red spot in the macula, and arteriolar narrowing or slugging with retinal 
arterioles irregularities in their caliber (Bertram et al 1995; Ben-Ami et al 2002; Cahill 
et al 2003; Chua et al 2006).
Fundus changes of BRAO are white, ischemic retina in the area supplied by an 
obstructed artery. In addition, capillary changes have also been described.
RAO is a multifactorial disorder. Next to the role of cardiovascular risk fac-
tors, thrombophilic factors have also been shown to play a role. The exact etiology 
and pathogenesis for RAO is still not clear (Müller et al 1992; Wenzel et al 1993; 
Bertram et al 1995; Geigner et al 1999; Pianka et al 2000; Saloman et al 2001; Clinical Ophthalmology 2008:2(3) 558
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Ben-Ami et al 2002; Weger et al 2003; Stojakovic et al 
2007). This is one of the reasons why targeted therapy for 
RAO is not available.
Our study investigated the pathogenetic factors from the 
widely accepted, so-called “acquired” cardiovascular risk 
factors (hypertension, hypercholesterolemia) in parallel with 
thrombophilic risk factors (Müller et al 1992; Geigner et al 
1999; Pianka et al 2000). We predict that our knowledge of 
the pathogenetic risk factors of RAO may enable us to deﬁ  ne 
therapy and secondary prophylaxis as well.
Patients and methods
Between 1997 and January of 2006, we studied 28 RAO 
patients and 81 age- and sex-matched control subjects in 
our Department of Ophthalmology within the Division of 
Rare Diseases. The mean age was 61.1 (±12.3) years in the 
RAO patients and 61.6 (±12.6) years the control subjects. 
The inclusion criteria for RAO were: sudden, painless loss 
of vision, presence of relative afferent pupillary defects, 
characteristic visual ﬁ  eld defects, and fundus changes. 
The following fundoscopic ﬁ  ndings were recorded: pale, 
ischemic retinal edema with a cherry red spot in the 
macula, and arteriolar narrowing or slugging with retinal 
arterioles irregularities in their caliber. Whenever the above 
changes were detected in all the four arterioles’ branches 
we referred to it as central occlusion (CRAO), and if one 
arteriole area was seen, the branch occlusion (BRAO) was 
established.
Exclusion criteria for patients with RAO comprised 
malignancy and vasculitis. To exclude vasculitis, the erythro-
cyte sedimentation rate (ESR) and C-reactive protein (CRP) 
levels were determined. The possibility of vasculitis was 
considered when the ESR level was higher than 33 mm/h 
and 35 mm/h in men and women, respectively, or when the 
CRP was higher than 0.5 mmol/l. We examined the pres-
ence of general symptoms such as headache, muscle ache, 
other, etc.
The control group consisted of 81 age- and sex-matched 
patients who have previously undergone cataract surgery, 
and subsequently presented retinal vascular diseases. In 
this case, at least one year had passed between the cataract 
surgery and the follow-up examination. No patients had 
suffered from autoimmune diseases. All patients were given 
detailed description of the main points of the examination, to 
which they then gave their written consent. We registered the 
previous diseases and medical therapy of our patients prior to 
their ﬁ  rst ophthalmologic examination. Those patients who 
were considered hypertensive, in that an internal medicine 
specialist had diagnosed them based on a measurement 
of higher than 140/90 mmHg on several occasions, also 
received scheduled controls as well as antihypertensive 
therapy. Patients suffering from hypercholesterolemia (above 
5.2 mmol/l) or hypertriglyceridemia (above 1.2 mmol/l) took 
part in oral antihyperlipidemic therapy.
All the patients control groups were subjected to a 
complete ophthalmologic examination, including best cor-
rected visual acuity, a visual ﬁ  eld test using Goldmann 
perimetry when visual acuity allowed it, intraocular pressure 
measurement using Goldmann applanation tonometry, slit 
lamp biomicroscopy and fundoscopy, as well as ﬂ  uorescein 
angiography.
The risk factors (hypertension, diabetes mellitus, isch-
emic heart disease, arteriosclerosis, and smoking) of each 
patient were also documented. In addition to the routine 
laboratory investigations, the level of serum cholesterol and 
triglyceride were measured, and an hemostasis screening test 
(prothrombin time, thrombin time, activated partial throm-
boplastin time) was performed. The starting date of the ﬁ  rst 
ophthalmologic symptoms was noted and six weeks later 
the blood samples were taken to evaluate thrombophilic risk 
factors: protein C (PC) and protein S (PS) levels, antithrom-
binopathy (AT), activated protein-C (APC) resistance and 
Leiden mutation, presence of FII G20210A allele, ﬁ  brinogen 
level, anticardiolipin – antiphospholipid (ACL-APL) antibod-
ies, elevated levels of factor VIII (FVIII), plasminogen, and 
lipoprotein-a (Lp(a)). The level of FVIII was considered 
elevated only when it increased in three consecutive measure-
ments, made at 6-week intervals after the initial screening. 
This way, we could ﬁ  lter out the false positive results. Since 
FVIII also plays a role as an acute phase protein, elevated 
levels can be found in the acute RAO phase without actually 
having any pathological role. We have followed the same 
protocol for the determination of decreased levels of PC, 
PS, and AT.
Control examinations were dated 6 weeks, 3 to 6 months, 
and one year after the initial examination. The total follow 
up time was between 11 months to 9 years. Nine patients 
were followed over a 9 year period.
Laboratory methods
All laboratory analysis was performed at the Department of 
Clinical Biochemistry and Molecular Pathology, University 
of Debrecen Medical and Health Science Center, Debrecen, 
Hungary.
Determinations of lipid (triglyceride, cholesterol) levels 
were performed using the enzymatic colorimetric method Clinical Ophthalmology 2008:2(3) 559
Thrombophilic screening in retinal artery occlusion patients
in a P800 modular chemical analyzer (Roche Diagnostics, 
Mannheim, Germany). Fibrinogen levels were determined 
according to the Clauss method (Clauss 1957). PC and PS 
activities were measured using coagulation tests (Diag-
nostica Stago). AT and plasminogen were determined by 
chromogenic assays (Diagnostica Stago). FVIII was deter-
mined using a clotting assay. All these determinations were 
performed in an STA-Compact coagulometer (Diagnostica 
Stago). FV Leiden mutation and FII G20210A allele were 
detected using a real-time polymerase chain reaction (RT-
PCR) method according to Bertram and colleagues (1995).
Determination of the activated protein-C (APC-R) ratio 
was achieved by the measurement of two different activated 
partial thromboplastin time (APTT). One measurement 
represented the plasma with APC, the other one without 
APC. The APC ratio is the ratio between these two measure-
ments, which we have considered positive at the level of 2 
or higher. In positive cases, the existence of the Leiden-
mutation is always justiﬁ  ed by molecular genetic methods. 
The potentially abnormal DNA sequences were ampliﬁ  ed 
by polymerase chain reaction (PCR). The PCR products 
were digested with restriction endonuclease (MnII), and 
the restriction fragments were separated by agars gel elec-
trophoresis. PCR method was used for the identiﬁ  cation of 
the FII G20210A allele. An enzyme-linked immunosorbent 
assay (Selisa, Cambridge Life Sciences, UK) was performed 
to determine the antibody against ACL. Lp(a) concentra-
tion was measured using a chemical method in an Integra 
700 automat (Roche Diagnostics). Homocysteine levels 
were determined by combined enzymatic and ﬂ  uorescent 
polarization immune method. In this procedure, all the 
homocysteine content of the samples is ﬁ  rst converted to 
S-adenosyl homocysteine (SAH). This product then 
competes with a manufacturer labeled SAH analogue for 
antibody binding. The amount of ﬂ  uorescent analogue was 
measured by polarizing immune method.
Statistical analysis
The homogeneous distribution of age and gender among 
RAO patients and control subjects was conﬁ  rmed by the 
Mann-Whitney test and chi-squared test respectively. Patients 
and control subjects were compared using Student’s t-test 
for parameters showing normal distribution, or the Mann-
Whitney test when the parameters’ distribution was not 
normal (p1 = 0.71, p2 = 0.11).
The thrombophilic and cardiovascular risk factors were 
analyzed by logistic regression odds ratios with 95% conﬁ  -
dence intervals. p-values lower than 0.05 were considered 
signiﬁ  cant. The statistical analysis was performed with SPSS 
version 11.5 (SPSS Inc., Chicago, IL).
Results
The mean age of the 16 male and 12 female patients with 
RAO was 61.12 (±12.3) years, while that of the control 
group was 61.6 (±12.6) years, with a male/female ratio of 
53/28 (Table 1).
CRAO was seen in 20 patients, and BRAO was devel-
oped in 9 patients. In the RAO patients, logistic regression 
Table 1 Statistical data of retinal artery occlusion patients in cardiovascular and thrombophilic risk factors
Cardiovascular risk factors  Odds ratio  95% Conﬁ  dence interval  p
Hypertriglyceridemia 1.32  0.58–2.99  0.50
Hypercholesterinemia 1.66  0.73–3.77  0.22
Ischemic heart disease  0.78  0.23–2.65  0.69
Hypertension 3.33  1.30–9.70  0.014
Diabetes mellitus  1.03  0.35–2.97  0.95
Current smoking  0.54  0.05–5.03  0.59
  Thrombophilic risk factors  
Hyperﬁ  brinogenemia  2.91  1.29–6.57  0.010
Elevated FVIII  0.78  0.35–1.73  0.54
FV ( Leiden)  3.96  1.43–10.96  0.008
FII G20210A allel  Not estimated (No cases)   
PC ↓  Not estimated (1 case)   
PS ↓  Not estimated (2 cases)   
Antithrombinopathy  Not estimated (2 cases)   
Plasminogen ↓ 1.12  0.26–4.75  0.87
Lipoprotein(a) ↑ 0.82  0.33–2.02  0.67
Hyperhomocysteinemia 1.47  0.66–3.25  0.34
Abbreviations: FVIII, factor VIII FV(Leiden), factor V of Leiden mutation; FII G20210A, factor II gene polimorphism, G20210A allele; PC↓, decreased level of proteine C; 
PS↓, decreased level of proteine S; plasminogen ↓, decreased level of plasminogen; Lipoprotein(a)↑, increased level of lipoprotein(a).Clinical Ophthalmology 2008:2(3) 560
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odds ratios with 95% conﬁ  dence interval were compared 
for cardiovascular risk factor. Hypertension (OR: 3.33, 95% 
CI: 1.30–9.70, p = 0.014), as an average risk factor, showed 
signiﬁ  cant difference, but thrombophilic risk factors such as 
hyperﬁ  brinogenemia (OR: 2.9, 95% CI: 1.29–6.57, p = 0.010) 
and the presence of APC-resistance FV (Leiden mutation) 
(OR: 3.9, 95% CI: 1.43–10.96, p = 0.008) increased the 
chances of developing this disease.
Statistical analysis could not be performed for other 
thrombophilic factors such as decrease in PC and PS activi-
ties, presence of FII 20210A allele and increase in FVIII, as 
thrombophilic changes could be observed in only 5 cases of 
those affected, and none in the control patients. In one case 
PC was observed, while a PS decrease was demonstrated in 
2 cases, and AT were shown in 2 other patients. No patient 
demonstrated any difference in the F II G20210A allele 
(Table 2).
Bilateral cases had not developed during the follow-up 
period.
Discussion
The multifactorial nature of RAO has been well documented. 
It may be caused by embolization from the internal carotid 
artery (thromboemboli or cholesterol emboli originating in 
atherosclerotic plaques of the carotid arteries), but rarely 
from the heart (eg, atrial ﬁ  brillation, aortic or mitral valve 
disease, endocarditis and atrial myxoma) (Müller et al 1992; 
Richard et al 1996; Rumelt et al 1999). The other important 
risk factors of RAO pathogenesis are cardiovascular risk fac-
tors such as hypertension, aortic diseases, diabetes mellitus, 
atherothrombosis, and current smoking.
Coagulation abnormalities in can play a role its 
development (Müller et al 1992; Richard et al 1996; Rumelt 
et al 1999; Pianka et al 2000; Salomon et al 2001; Stojakovic 
2007). Increased coagulation may cause ischemic retinal 
infarction by decreased blood ﬂ  ow of the retinal arterioles. 
In some cases RAO cannot be explained with the known 
factors alone thus identiﬁ  cation of other unknown risk fac-
tors such as thrombophilic risk factors should be considered 
(Ben-Ami et al 2002).
Weger and colleagues (2003) and Pianka and colleagues 
(2000) stated that increased homocysteine level plays a 
role in the development of RAO (Wenzel et al 1993; Cahill 
et al 2003; Chua et al 2006). In our patients who suffered 
from RAO, we frequently found such a signiﬁ  cant increase. 
No correlation was found in the methyltetrahydrofolate 
reductase gene polymorphism between the patients and 
the controls.
Müller and colleagues (1992) proved that the increased 
Lp(a) level has a pathological role in the development of 
RAO. Elevated Lp(a) level can cause arteriosclerotic changes 
in small arterioles in the carotid system on one hand, and on 
the other hand, it is considered as a thrombophilic factor due 
to its antiﬁ  brinolytic effect. Lp(a) binding to plasminogen 
receptors in the blood vessel endothelium competitively 
inhibits plaminogen-plasmin transformation. High Lp(a) lev-
els and decreased plasminogen levels have synergistic effects 
in further increasing thrombophilic risk when both are present 
at the same time (Müller et al 1992; Stojakovic et al 2007). 
Plasma Lp(a) levels are high in patients with central retinal 
artery occlusion. Elevated lipoprotein-a serum level is an 
established risk factor in cardiovascular and cerebrovascular 
Table 2 Statistical data of RAO patients by Mann-Whitney test
Cardiovascular risk factors  Mean value  Standard deviation  Minimum and
(normal level)      maximal value
Hypertriglyceridemia (1.2 mmol/l)  1.55  ±0.68 0.77–3.53
Hypercholesterolemia (5.2 mmol/l)  5.92  ±1.23 4.17–8.29
Thrombophilic risk factors  
Fibrinogen level (4.0 g/l)  4.29  ±1.66 2.25–10.56
FVIII level (150%) 191.03%  ±57.28 126–312
FV (Leiden) mutation (number of heterozygote)  4   
FII G20210A allel  No case   
PC level (70%) (1  case)  137.28  ± 29.93  67–193
PS level (65%) (2  cases)  108.35  ±20.24 54–144
AT level (80%) (2  cases)  114.03  ±11.28 76–127
Plasminogen level (80%) 105.38  ±15.23 70–221
Lp(a) level (300 mg/l)  385.24  ±367.2 102–1325
Homocystein level (12.5 μmol/l) 15.41  ±12.0 10.67–39.43
Abbreviations: FVIII, factor VIII; FV(Leiden), factor V of Leiden mutation; FII G20210A, factor II gene polimorphism, G20210A allele; PC↓, decreased level of proteine C; PS↓, 
decreased level of proteine S; plasminogen ↓, decreased level of plasminogen; Lipoprotein(a)↑, increased level of lipoprotein(a).Clinical Ophthalmology 2008:2(3) 561
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diseases. It may have a role in damaging the circulation of the 
retinal arteries, which may lead to retinal infarction (Müller 
et al 1992; Stojakovic et al 2007).
Ben-Ami and colleagues (2002) reported showed such 
case in a 19 year-old-male patient who, despite his young 
age, developed CRAO in one eye. The patient suffered from 
no cardiovascular disease and no risk factors could be shown. 
During the thrombophilic screening, this patient had a homo-
zygous FV Leiden mutation and heterozygous prothombin 
G20210A polymorphism (Ben-Ami et al 2002).
In the present study, we examined the importance of 
thrombophilic risk factors in the development of retinal 
artery occlusion. Our study found that the CRAO-patients 
have signiﬁ  cantly in higher number a FV Leiden mutation, 
elevated homocysteine level and Lp(a), and our data shows 
that both cardiovascular and thrombophilic risk factors may 
have an important role in the development of RAO. Based 
on our data, we suggest that thrombophilia with or without 
the presence of vascular damage may have a key role in the 
development of RAO.
In the case of thrombophilia, causal therapy is also 
available. It has been proven that cessation of smoking, in 
conjunction with the administration of vitamins B6, B12, and 
folic acid, is beneﬁ  cial in the treatment of homocysteinemia 
(Wenzel et al 1993; Pianka et al 2000; Cahill et al 2003; 
Chua et al 2006). When dealing with acute fundus vascular 
pathology CRAO, the introduction of ﬁ  brinolytic therapy 
is highly recommended (Richard et al 1996; Rumelt et al 
1999). Unless otherwise contraindicated, the introduction of 
thrombolytic therapy should be introduced within 6 hours 
after the onset of thrombosis. The thrombolytic therapy 
requires emergency room setting and professional staff. Due 
to the danger of heavy bleeding side effects, this treatment 
should not be expanded to a wider circle. It is important to 
ﬁ  nd another effective therapy with lesser side effects.
In the event that thrombophilia has been proved as exist-
ing alongside cardiovascular risk factors, we recommend 
antithrombotic therapy implemented together with the cir-
culation-improving therapy. Antithrombocyte – antiplatelet 
therapy with salicylates may prove effective, or, if contra-
indicated, antiplatelet therapy per os is recommended. With 
this kind of therapy, the likelihood of the development of 
another arterial event in the other eye decreases.
Thrombophilic screening is recommended for RAO 
patients under the age of 50, or with bilateral fundus vascular 
pathology. We recommended thrombophilic screening to 
other family members if RAO has occurred in the family and 
the patient has at least 2 strong thrombophilic factors: FV 
Leiden mutation, PS- or PC-decrease, etc. If cardiovascular 
risk factors are also present alongside thrombophilic risk fac-
tors, then chance of developing RAO gets multiplied. Positive 
family anamnesis after thrombophilia in selected cases raises 
a possibility for primary prevention with antithrombotic/
antiplatelet therapy.
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